91 research outputs found
The clinical use of Kampo medicines (traditional Japanese herbal treatments) for controlling cancer patientsâ symptoms in Japan: a national cross-sectional survey
Optical biosensor differentiates signaling of endogenous PAR1 and PAR2 in A431 cells
<p>Abstract</p> <p>Background</p> <p>Protease activated receptors (PARs) consist of a family of four G protein-coupled receptors. Many types of cells express several PARs, whose physiological significance is mostly unknown.</p> <p>Results</p> <p>Here, we show that non-invasive resonant waveguide grating (RWG) biosensor differentiates signaling of endogenous protease activated receptor subtype 1 (PAR<sub>1</sub>) and 2 (PAR<sub>2</sub>) in human epidermoid carcinoma A431 cells. The biosensor directly measures dynamic mass redistribution (DMR) resulted from ligand-induced receptor activation in adherent cells. In A431, both PAR<sub>1 </sub>and PAR<sub>2 </sub>agonists, but neither PAR<sub>3 </sub>nor PAR<sub>4 </sub>agonists, trigger dose-dependent Ca<sup>2+ </sup>mobilization as well as G<sub>q</sub>-type DMR signals. Both Ca<sup>2+ </sup>flux and DMR signals display comparable desensitization patterns upon repeated stimulation with different combinations of agonists. However, PAR<sub>1 </sub>and PAR<sub>2 </sub>exhibit distinct kinetics of receptor re-sensitization. Furthermore, both trypsin- and thrombin-induced Ca<sup>2+ </sup>flux signals show almost identical dependence on cell surface cholesterol level, but their corresponding DMR signals present different sensitivities.</p> <p>Conclusion</p> <p>Optical biosensor provides an alternative readout for examining receptor activation under physiologically relevant conditions, and differentiates the signaling of endogenous PAR<sub>1 </sub>and PAR<sub>2 </sub>in A431.</p
Impaired cardiac and peripheral hemodynamic responses to inhaled ÎČ2-agonist in cystic fibrosis
Recommended from our members
Assessing performance of the Healthcare Access and Quality Index, overall and by select age groups, for 204 countries and territories, 1990â2019: a systematic analysis from the Global Burden of Disease Study 2019
Background
Health-care needs change throughout the life course. It is thus crucial to assess whether health systems provide access to quality health care for all ages. Drawing from the Global Burden of Diseases, Injuries, and Risk Factors Study 2019 (GBD 2019), we measured the Healthcare Access and Quality (HAQ) Index overall and for select age groups in 204 locations from 1990 to 2019.
Methods
We distinguished the overall HAQ Index (ages 0â74 years) from scores for select age groups: the young (ages 0â14 years), working (ages 15â64 years), and post-working (ages 65â74 years) groups. For GBD 2019, HAQ Index construction methods were updated to use the arithmetic mean of scaled mortality-to-incidence ratios (MIRs) and risk-standardised death rates (RSDRs) for 32 causes of death that should not occur in the presence of timely, quality health care. Across locations and years, MIRs and RSDRs were scaled from 0 (worst) to 100 (best) separately, putting the HAQ Index on a different relative scale for each age group. We estimated absolute convergence for each group on the basis of whether the HAQ Index grew faster in absolute terms between 1990 and 2019 in countries with lower 1990 HAQ Index scores than countries with higher 1990 HAQ Index scores and by Socio-demographic Index (SDI) quintile. SDI is a summary metric of overall development.
Findings
Between 1990 and 2019, the HAQ Index increased overall (by 19·6 points, 95% uncertainty interval 17·9â21·3), as well as among the young (22·5, 19·9â24·7), working (17·2, 15·2â19·1), and post-working (15·1, 13·2â17·0) age groups. Large differences in HAQ Index scores were present across SDI levels in 2019, with the overall index ranging from 30·7 (28·6â33·0) on average in low-SDI countries to 83·4 (82·4â84·3) on average in high-SDI countries. Similarly large ranges between low-SDI and high-SDI countries, respectively, were estimated in the HAQ Index for the young (40·4â89·0), working (33·8â82·8), and post-working (30·4â79·1) groups. Absolute convergence in HAQ Index was estimated in the young group only. In contrast, divergence was estimated among the working and post-working groups, driven by slow progress in low-SDI countries.
Interpretation
Although major gaps remain across levels of social and economic development, convergence in the young group is an encouraging sign of reduced disparities in health-care access and quality. However, divergence in the working and post-working groups indicates that health-care access and quality is lagging at lower levels of social and economic development. To meet the needs of ageing populations, health systems need to improve health-care access and quality for working-age adults and older populations while continuing to realise gains among the young
Postoperative blood pressure deficit and acute kidney injury progression in vasopressor-dependent cardiovascular surgery patients
BACKGROUND: In vasopressor-dependent patients who had undergone cardiovascular surgery, we examined whether those with progression of acute kidney injury (AKI) had a greater difference (deficit) between premorbid and within-ICU hemodynamic pressure-related parameters compared to those without AKI progression. METHODS: We assessed consecutive adults who underwent cardiovascular surgery and who stayed in our ICU for at least 48 hours and received vasopressor support for more than 4 hours. We obtained premorbid and vasopressor-associated, time-weighted average values for hemodynamic pressure-related parameters (systolic [SAP], diastolic [DAP], and mean arterial pressure [MAP]; central venous pressure [CVP], mean perfusion pressure [MPP], and diastolic perfusion pressure [DPP]) and calculated deficits in those values. We defined AKI progression as an increase of at least one Kidney Disease: Improving Global Outcomes stage. RESULTS: We screened 159 patients who satisfied the inclusion criteria and identified 76 eligible patients. Thirty-six patients (47%) had AKI progression. All achieved pressure-related values were similar between patients with or without AKI progression. However, deficits in DAP (P = 0.027), MPP (P = 0.023), and DPP (P = 0.002) were significantly greater in patients with AKI progression. CONCLUSIONS: Patients with AKI progression had greater DAP, MPP, and DPP deficits compared to patients without AKI progression. Such deficits might be modifiable risk factors for the prevention of AKI progression
REPEATABILITY IN TWO CONSECUTIVE 24-HOUR BLOOD PRESSURE AND HEART RATE PATTERNS IN NORMOTENSIVE SUBJECTS.
Modeling Early Dose-Effect Bone Changes in Children Irradiated for Embryonal Rhabdomyosarcoma of the Orbit
Carrier-mediated processes in blood-brain barrier penetration and neural uptake of paraquat
ELSEVIER, Ishimoto, T; Omori, N; Mutoh, F; Chiba, S, BRAIN RESEARCH, 906(1-2), 152-158, 2001.
authorDue to the structural similarity to N-methyl-4-phenyl pyridinium (MPP+), paraquat might induce dopaminergic toxicity in the brain. However, its blood-brain barrier (BBB) penetration has not been well documented. We studied the manner of BBB penetration and neural cell uptake of paraquat using a brain microdialysis technique with the HPLC/UV detection in rats. After subcutaneous administration, paraquat appeared dose-dependently in the dialysate. In contrast, MPP+ could not penetrate the BBB in either control or paraquat pre-treated rats. These data indicated that the penetration of paraquat into the brain would be mediated by a specific carrier process, not resulting from the destruction of the BBB function by paraquat itself or a paraquat radical. To examine whether paraquat was carried across the BBB by a certain amino acid transporter, L-valine or L-lysine was pre-administered as a co-substrate. The pre-treatment of L-valine, which is a high affinity substrate for the neutral amino acid transporter, markedly reduced the BBB penetration of paraquat. When paraquat was administered to the striatum through a microdialysis probe, a significant amount of paraquat was detected in the striatal cells after a sequential 180-min washout with Ringer's solution. This uptake was significantly inhibited by a low Na+ condition, but not by treatment with putrescine, a potent uptake inhibitor of paraquat into lung tissue. These findings indicated that paraquat is possibly taken up into the brain by the neutral amino acid transport system, then transported into striatal, possibly neuronal, cells in a Na+-dependent manner
Treatment Outcomes Following 45 GyRBE to a Post-Induction Target Volume in Children with Group III Orbital Embryonal Rhabdomyosarcoma
- âŠ